Anthony Letai

Research.com Recognitions

• Member of the Association of American Physicians
• Member of the Association of American Physicians
• Member of the Association of American Physicians

Overview

Best Publications

• The landscape of somatic copy-number alteration across human cancers

  Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  4301
  Citations

• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  Tilman Oltersdorf;Steven W. Elmore;Alexander R. Shoemaker;Robert C. Armstrong

  4097
  Citations

• Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

  Anthony Letai;Michael C. Bassik;Loren D. Walensky;Mia D. Sorcinelli

  2098
  Citations

• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

  Courtney D DiNardo;Brian A Jonas;Vinod Pullarkat;Michael J Thirman

  1941
  Citations

• Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

  Rumani Singh;Anthony Letai;Kristopher Sarosiek

  1642
  Citations

• Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

  Courtney D. DiNardo;Keith Pratz;Vinod Pullarkat;Brian A. Jonas

  1587
  Citations

• Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

  Michael Certo;Victoria Del Gaizo Moore;Mari Nishino;Guo Wei

  1508
  Citations

• Control of mitochondrial apoptosis by the Bcl-2 family.

  Joslyn K. Brunelle;Anthony Letai

  1105
  Citations

• Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1

  Joseph T. Opferman;Anthony Letai;Caroline Beard;Mia D. Sorcinelli

  1001
  Citations

• Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

  Marina Konopleva;Daniel A. Pollyea;Jalaja Potluri;Brenda Chyla

  949
  Citations

• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

  Dharminder Chauhan;Laurence Catley;Guilan Li;Klaus Podar

  839
  Citations

• Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

  Courtney D DiNardo;Keith W Pratz;Anthony Letai;Brian A Jonas

  763
  Citations

• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

  Victoria Del Gaizo Moore;Jennifer R. Brown;Michael Certo;Tara M. Love

  716
  Citations

• Diagnosing and exploiting cancer's addiction to blocks in apoptosis

  Anthony G. Letai

  690
  Citations

• Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

  Rongqing Pan;Leah J. Hogdal;Juliana M. Benito;Donna Bucci

  668
  Citations

• Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

  Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  637
  Citations

• BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

  Jing Deng;Nicole Carlson;Kunihiko Takeyama;Paola Dal Cin

  594
  Citations

• Precision medicine for cancer with next-generation functional diagnostics

  Adam A. Friedman;Anthony Letai;David E. Fisher;Keith T. Flaherty

  563
  Citations

• Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

  Jennifer L. Guerriero;Alaba Sotayo;Holly E. Ponichtera;Jessica A. Castrillon

  476
  Citations

• Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

  Derek Yecies;Nicole E. Carlson;Jing Deng;Anthony Letai

  416
  Citations